Sign in

Research summary ·

Pharmacological treatments of REM sleep behaviour disorder in synucleinopathies: a systematic review of effectiveness and safety.

Written based on 1 research study on PubMed, searched on 3 Nov 2026.

What was studied

This was a review of drugs for REM sleep behaviour disorder (RBD). The review covered RBD in several related brain diseases. These were Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies. They also included multiple system atrophy and isolated RBD. Only studies with a sleep lab video test to confirm RBD were used. The team searched MEDLINE/PubMed, Embase and the Cochrane Library up to 1 March 2026. In all, 18 studies met the criteria. Designs differed, so results were told in words.

What they found

Clonazepam, melatonin and pramipexole were the most studied drugs. Clonazepam showed a possible gain. It also raised safety worries in vulnerable groups with these diseases. Melatonin seemed easier to take. Its effect varied by disease type. Other drugs had only early data. Gains reported by patients were more common than gains on sleep tests.

What it means for patients

The authors say the evidence for RBD care in these diseases is limited and mixed. They say clonazepam and melatonin stay the main drugs in use. They say larger trials with set clinical and sleep lab outcomes are needed.

Why it is not certain yet

Evidence was limited and mixed. No firm view on melatonin by subgroup is yet possible. Designs and outcomes differed, so results were not pooled. A review can only be as good as the studies in it.

Source

Pharmacological treatments of REM sleep behaviour disorder in synucleinopathies: a systematic review of effectiveness and safety.

PubMed · PMID 42623795

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Lewy body dementia publications